<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001054</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 253</org_study_id>
    <secondary_id>11230</secondary_id>
    <nct_id>NCT00001054</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children</brief_title>
  <official_title>A Phase I Trial to Evaluate the Pharmacokinetics, Safety, and Tolerance of Valacyclovir HCl in HIV-1 Infected Children With Herpes Simplex Infections or Varicella/Zoster Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To obtain tolerance, safety, and pharmacokinetic data for oral valacyclovir hydrochloride (&#xD;
      256U87 ) in HIV-1 infected children with herpes simplex virus infections ( cold sores )&#xD;
      and/or varicella / zoster virus infections ( chicken pox / shingles ).&#xD;
&#xD;
      Varicella and zoster are common problems in HIV-infected children. It is believed that&#xD;
      chronic oral therapy with acyclovir may result in subtherapeutic concentrations of acyclovir,&#xD;
      resulting in resistance to that drug. Valacyclovir hydrochloride, which converts to acyclovir&#xD;
      in the body, increases acyclovir bioavailability by 3-5 fold.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Varicella and zoster are common problems in HIV-infected children. It is believed that&#xD;
      chronic oral therapy with acyclovir may result in subtherapeutic concentrations of acyclovir,&#xD;
      resulting in resistance to that drug. Valacyclovir hydrochloride, which converts to acyclovir&#xD;
      in the body, increases acyclovir bioavailability by 3-5 fold.&#xD;
&#xD;
      In the first cohort, patients with stable herpes simplex virus receive valacyclovir&#xD;
      hydrochloride at 1 of 2 doses, depending on body surface area (BSA), for 10 days. If&#xD;
      acceptable safety is seen at this dose level, a second cohort of patients with stable herpes&#xD;
      simplex virus receive a higher dose, depending on BSA, for 10 days. A third cohort of&#xD;
      patients with varicella or zoster receive a selected dose based on results from the previous&#xD;
      cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <completion_date type="Actual">January 2001</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Herpes Simplex</condition>
  <condition>HIV Infections</condition>
  <condition>Chickenpox</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretrovirals.&#xD;
&#xD;
          -  PCP prophylaxis.&#xD;
&#xD;
          -  IVIG, G-CSF, and erythropoietin.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Transfusions.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Localized mucocutaneous herpes simplex OR undisseminated varicella or zoster.&#xD;
&#xD;
          -  HIV positive. NOTE: Varicella patients must NOT have AIDS.&#xD;
&#xD;
          -  CD4 count &gt;= 100 cells/mm3 (herpes simplex or zoster patients) OR &gt;= 250 cells/mm3&#xD;
             (varicella patients).&#xD;
&#xD;
          -  BSA &gt; 0.6 m2.&#xD;
&#xD;
          -  Ability to swallow solid dosage formulations.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior VZV immune globulin and/or IVIG.&#xD;
&#xD;
          -  Antiretrovirals if at a stable dose for at least 14 days.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Clinical evidence of pneumonitis.&#xD;
&#xD;
          -  Severe abdominal pain or back pain.&#xD;
&#xD;
          -  Encephalopathy.&#xD;
&#xD;
          -  Hemorrhagic varicella.&#xD;
&#xD;
          -  Zoster involving ophthalmic branch of trigeminal nerve.&#xD;
&#xD;
          -  Severe gastrointestinal disorder.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Agents with potential activity against HSV or VZV, such as acyclovir, famciclovir,&#xD;
             ganciclovir, foscarnet, and sorivudine.&#xD;
&#xD;
          -  Probenecid.&#xD;
&#xD;
          -  Aspartamine within 48 hours prior to pharmacokinetic samplings.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Grade 2 creatinine value within the past 30 days.&#xD;
&#xD;
          -  Grade 3 hematologic or hepatic values within the past 30 days.&#xD;
&#xD;
          -  Prior hypersensitivity and/or allergic reaction to acyclovir.&#xD;
&#xD;
          -  Grade 3 or 4 mental status changes within the past 30 days.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acyclovir within 1 week prior to study entry.&#xD;
&#xD;
          -  Steroids within 4 weeks prior to onset of varicella lesions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keller MA</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Bryson Y</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Gershon A</last_name>
    <role>Study Chair</role>
  </overall_official>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>von Seidlein L, Gillette SG, Bryson Y, Frederick T, Mascola L, Church J, Brunell P, Kovacs A, Deveikis A, Keller M. Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. J Pediatr. 1996 Jan;128(1):52-7. doi: 10.1016/s0022-3476(96)70427-4.</citation>
    <PMID>8551421</PMID>
  </reference>
  <reference>
    <citation>Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med. 1999 Jun 1;130(11):922-32. doi: 10.7326/0003-4819-130-11-199906010-00017.</citation>
    <PMID>10375341</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes Zoster</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Herpes Simplex</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>valacyclovir</keyword>
  <keyword>Chickenpox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

